Key result
Serum ischemia-modified albumin levels are elevated in acute coronary syndrome vs. controls at ~120 ng/mL.
Case-Control (n=120)
No
Answers are grounded in this paper and cite their sources.
Elevated ischemia-modified albumin may support biomarker research in acute coronary syndrome; leaves open clinical adoption pending validation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Sadanandam et al. (2026) conducted a case-control in Acute Coronary Syndrome (n=120). Acute Coronary Syndrome vs. Healthy controls was evaluated on Median ischemia-modified albumin (IMA) level (ng/mL) (p=<0.001). Median serum ischemia-modified albumin levels were significantly elevated in patients with acute coronary syndrome (120 ng/mL) compared to healthy controls (86 ng/mL).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: